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j Abstract Background Generalized anxiety disor-
der (GAD) is generally considered to be a chronic
condition, waxing and waning in severity; however
prospective investigation of the course of GAD in
community samples is lacking. This study seeks to fill
that gap, by identifying the whole spectrum of gen-
eralized anxiety syndromes, sub-typing them
according to their duration and frequency of occur-
rence, and evaluating their long-term course and
outcome in the community. Method The prospective
Zurich Study assessed psychiatric and somatic syn-
dromes in a community sample of young adults
(N = 591) (aged 20 years at first interview) by six
interviews over a period of 20 years (1979–1999).
GAD syndromes were defined by DSM-III symptom
criteria without applying any exclusion criteria. A
spectrum of generalized anxiety was defined by
duration: 6 months (DSM-IV), 1 month (DSM-III),
£2 weeks (with weekly occurrence over one year), and
anxiety symptoms. From 1978 (screening) to 1999 the
annual presence of symptoms and treatment was as-
sessed. Persistence of anxiety was defined by the al-
most daily presence of symptoms over the previous
12 months. Results The annual incidence of DSM-III
GAD increased considerably between the ages of 20
and 40. The average age of onset of symptoms was
15.6 years; in 75% of cases it occurred before the age
of 20. 75 of 105 DSM-III GAD cases had at least one
follow-up. At their individual last follow-up, 12 of
those 75 subjects (16%) were re-diagnosed as having
GAD, 22 (29%) manifested subthreshold syndromes
or anxiety symptoms, while 39 cases, the majority,
(52%) were symptom-free; 5 of the 12 re-diagnosed
GAD cases were persistent (corresponding to 7% of all
75 initial GAD cases). In their twenties they were
treated at some time in 6% of all years, but in their
thirties this figure rose to 12%. At their individual last
follow-up 26% of 6-month GAD subjects and 22% of
1-month GAD subjects were still being treated. Trea-
ted vs. non-treated subjects did not differ in terms of
gender but did differ in severity, persistence and in
comorbidity with bipolar-II disorder, social phobia,
obsessive-compulsive syndromes and substance-use
disorders. Limitations Results are based on a rela-
tively small sample and cannot be generalized to
adults aged over 40 years. Conclusions The course of
DSM-III-defined GAD may not be chronic, as previ-
ously suggested, but mainly recurrent with inter-
vening symptom-free periods of recovery in about
half of cases. Over a period of 20 years there was more
improvement than progression within the anxiety
spectrum.
j Key words generalized anxiety disorder Æ inci-
dence Æ onset Æ course Æ outcome Æ anxiety
spectrum
Introduction
Generalized anxiety disorder (GAD) is generally
considered to follow a chronic course, waxing and
waning in severity [1, 9, 24, 28]. GAD was observed to
be chronic for a decade or longer [22] with deterio-
rations during times of stress [1, 15].
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Barlow et al. [10] found that GAD patients tended
to spend more time being anxious than did patients
with panic disorder, a finding compatible with the
observations of Anderson et al. [2]. From a five-year
follow-up study of GAD patients, Woodman et al. [30]
reported that only 18% had remitted. Comorbid GAD
subjects are reported to manifest higher disability and
dysfunction than ‘pure’ cases, i.e. without comorbid-
ity [19, 26]. In the National Comorbidity Survey, the
course of GAD and its related impairment were not
connected with comorbidity with major depression
[20], which supports the independence of GAD as an
independent diagnostic entity.
However the results of the ‘Harvard/Brown Anxiety
Disorders Research Program’, a large 8-year follow-up
study of GAD and panic patients recruited from 11
psychiatric clinics are at variance with the cited evi-
dence for the chronicity of GAD. Yonkers et al. [31]
reported remission rates cumulatively for every year
of follow-up. After five years, 35% of men and 38% of
women with GAD showed full symptomatic remis-
sion, and after 8 years the proportions were 46 and
56%, respectively. Most remissions occurred within
the first 2 years. More recently Bruce et al. [13]
published a further follow-up of the same sample over
12 years: 58% of GAD cases had recovered, while the
probability of recurrence in recovered patients was
45%. Comorbidity with other psychiatric disorders
worsened the prognosis, with lower recovery and
higher recurrence rates. A remarkable remission rate
of 50% was also found in retrospect by Blazer et al.
[12] in three Epidemiologic Catchment Area Study
sites. Furthermore, in a recent 40-year follow-up
study of 59 GAD patients, only about 17% of patients
were re-diagnosed as having GAD, which tended to
disappear at around the age of 50 years [25].
This paper seeks to add the evidence provided by
prospective epidemiological data from the Zurich
Study on the course of the GAD spectrum over
20 years (subjects aged 20/21 to 40/41). It seems
reasonable to anticipate that the long-term prognosis
of GAD in a cohort of subjects from community set-
tings may be better than that of treated psychiatric
patients. We will also compare 1-month GAD
(reflecting DSM-III criteria) with 6-months GAD
(reflecting DSM-IV criteria), in terms of course and
outcome.
Methodology
j Sample selection and design of the study
The Zurich Study (a prospective epidemiological study of depres-
sive, neurotic and psychosomatic syndromes) was based at outset
on a sample of 4,547 subjects (m = 2,201; f = 2,346) representative
of the canton of Zurich in Switzerland in 1978 (population 1.1
million). All subjects were screened with the Symptom Checklist
90-R (SCL-90-R) [16], a comprehensive self-report questionnaire of
90 questions, which has been validated for that purpose and covers
a broad range of psychiatric symptoms. This investigation took
place in 1978 when the male participants were aged 19 years (at
conscription) and the females 20 years (at enrolment on the elec-
toral register). They were approached with the authorisation of the
government and the Departments of the Interior of their cantons of
residence.
In order to enrich the sample with cases at risk for the devel-
opment of psychiatric syndromes, a stratified sampling procedure
was chosen: a sub-sample of 591 subjects (292 males, 299 females)
was selected for interview, with two-thirds consisting of high
scorers (i.e. above the 85th percentile) on the Global Severity Index
of the SCL-90, and one-third being a random sample of those with
lower scores (i.e. below the 85th percentile). The stratified sample
represents, after weighting, 2,600 persons of the same age from the
general population. The theoretical basis of these stratified proce-
dures is described by Dunn et al. [17]. In our sample there were no
major differences in socio-demographics between males and fe-
males.
Details of sampling procedures and refusal rates were presented
in the first publication [3] and recently again [6]. Since screening in
1978, six interview waves have been conducted: in 1979 (ages 20/
21), 1981 (22/23), 1986 (27/28), 1988 (29/30), 1993 (34/35) and 1999
(40/41).
j Interviews
The structured psychopathological interview and rating of social
consequences of psychic disturbances for epidemiology (SPIKE)
was used [3]. The SPIKE assesses a series of somatic complaints,
including insomnia, headache, and gastrointestinal, cardiovascular,
respiratory, perimenstrual and sexual syndromes. It also assesses
depression, hypomania, anxiety, phobias, obsessive-compulsive
and fatigue syndromes, eating disorders, post-traumatic stress
disorder, substance abuse and suicidal phenomena. Each interview
covered the previous 12 months and was carried out in the sub-
jects’ homes with their informed consent, and in accordance with
the Declaration of Helsinki.
Validity and reliability testing have been carried out with par-
ticular reference to depression and anxiety [6]. All subjects were
approached for each interview (by letters informing them about the
study and guaranteeing medical secrecy), regardless of whether or
not they had participated in previous interviews, unless they had
explicitly stated their wish to withdraw from the study definitively.
Interviewers were mainly graduate clinical psychologists plus
some psychiatrists, both groups having had special interview
training. The inter-rater reliability of the SPIKE was found to be
high, with kappas of 0.89 and 0.91 for the symptoms of depression
and anxiety and of 0.90 for the corresponding syndromal diagno-
ses. Further methodological details were published by Angst et al.
[6]. 62.1% of the original sample remained in the study across
20 years, with the following participation rates: 47% in all six
interviews; 63% in five interviews; 74% in four interviews; 82% in
three interviews, and 91.4% in at least two interviews. Those who
dropped out of the study did not differ significantly from those who
remained until the most recent interview (1999) in terms of strat-
ified sampling and of most demographic characteristics [18].
j Diagnostic classification
Since 1980 the definitions of GAD have undergone considerable
modification with successive versions of the DSM and ICD. There is
substantial doubt about some of these changes [15]. In the case of
GAD it has been demonstrated that duration, e.g. one month (DSM-
III, ICD-9) or six months (DSM-III R, DSM-IV and ICD-10), was
not a relevant diagnostic criterion and did not reduce the degree of
comorbidity with depression [5, 11, 21]. Furthermore, application
of the 6-month criterion for GAD excludes about half of all patients
treated for the disorder in the general population; moreover, the
varying syndrome definitions in the above diagnostic manuals
merely describe the same symptom complex in different ways [5].
38
For this reason we defined a GAD syndrome, independently of
its duration, using DSM-III symptom criteria, i.e. by the presence of
3 of 4 symptom domains: motor tension, autonomic hyperactivity,
apprehensive expectation, vigilance and scanning. Exclusion crite-
ria were not applied. The shorter or milder manifestations of
anxiety existing under the temporal diagnostic threshold of DSM-
III GAD (1-month) are taken into account in this paper in order to
describe their transitions into diagnostic cases and vice versa. We
found some subjects with 2-week GAD syndromes and many more
with highly recurrent brief episodes of anxiety, termed recurrent
brief anxiety (RBA) [8]. The diagnosis of RBA required the pres-
ence of a DSM-III GAD syndrome of under 2 weeks’ duration (in
fact, usually only a few days) and high recurrence (at least monthly,
over 1 year).
For the purposes of this study the GAD severity spectrum was
defined by duration: 1 = GAD 6 months, 2 = GAD 1 month,
3 = GAD 2 weeks, 4 = RBA, 5 = anxiety symptoms, 6 = no
symptoms. DSM-III-R GAD of 6 months’ duration could not be
diagnosed until the 1993 and 1999 interviews (subjects aged 34/35
and 40/41), because the concept did not exist earlier. DSM-IV GAD
could be diagnosed in 1999 but no follow-up data is available yet.
j Course and outcome
Over the 22 years from 1978 to 1999 the presence or absence of
symptoms and treatment was assessed on the basis of ‘‘yes/no’’
replies for every year; in order to correct for drop-outs, the intra-
individual % years were computed. In all six interviews anxiety
was assessed with a stem question and a list of symptoms; a
symptom-free status was also defined in this way. In addition, at
every interview subjects were given the Symptom Check List 90R
(SCL-90-R), which measures several aspects of anxiety with the
sub-scales of anxiety, somatisation, phobia, obsessive-compulsive,
and interpersonal over-sensitivity. Mean scores on the scales of
anxiety and somatisation will also be given as measures of out-
come.
In addition, persistent GAD syndromes were defined from 1986
to 1999 (ages 27/28–40/41) by the ‘‘almost daily’’ presence of anx-
iety symptoms in the previous year and a minimum duration of the
episode of 3 months (1986, 1988) or 6 months (1993, 1999). Non-
persistent GAD syndromes comprise every GAD syndrome with a
minimum length of 2 weeks (RBA not included). We reserve the
term ‘‘chronic’’ for the description of the longitudinal course of
anxiety episodes over the whole study period. A chronic course
means the repeated occurrence of diagnostic or subdiagnostic
anxiety syndromes, whereas a recurrent course means the full
recovery or merely residual symptoms between episodes.
j Statistics
Frequencies were compared using v2—tests. Kruskal-Wallis tests
were used on continuous and rank-ordered data. The percentage of
years suffered or treated was intra-individually compared between
the first and second decade of the Zurich Study using Wilcoxon
sign-rank tests. A multivariable logistic regression was used to
compare treated to non-treated GAD cases in terms of comorbidity.
The initial full model was reduced by step-wise elimination of the
least significant predictor variable, until all remaining predictors
were significant at P < 0.10.
The follow-up of the first episode of GAD was analysed as fol-
lows: firstly, the first episode of 1+ month GAD was identified for
each subject who had ever had such an episode. The interview year
of the first episode could vary inter-individually. In a second step,
all subsequent interviews of a given subject were examined for the
occurrence of any anxiety state or symptom-free state. The
occurrence of any category of anxiety state was recorded: ‘‘no
anxiety symptoms’’, ‘‘anxiety symptoms’’, ‘‘RBA’’, ‘‘2-weeks GAD’’,
or ‘‘1+ month GAD’’. Thus, the reported percentages (Fig. 2, left-
hand side) refer to the percentage of subjects with a first episode of
1+ month GAD having had a particular anxiety state at any sub-
sequent interview. As various categories of anxiety state can follow
the initial episode of GAD, those percentages total more than 100%.
The analysis of the follow-back of the last individual episode of 1+
month GAD was carried out analogously. Analyses were done in
Stata 8.2 and SAS 8.2 for Windows.
Results
j The overlap between DSM-III GAD, RBA and panic
attacks
After adjustment for gender and stratified sampling,
all three diagnostic groups were significantly associ-
ated with each other: 1-month GAD was associated
with both panic attacks (41%; OR = 2.3) and RBA
(35%; OR = 1.7). Although recurrent brief anxiety
(RBA) was assessed and defined in the context of
GAD, it was strongly associated (55%; OR = 8.1) with
panic attacks. As a consequence of this finding, RBA
has been included in another report as a sub-diag-
nostic element of the panic spectrum, but has not
been excluded from the GAD spectrum in the present
paper.
j Incidence and age of onset of anxiety in subjects
with DSM-III GAD (1979–1999)
The one-year prevalence rates of DSM-III GAD in-
creased from 0.8% at age 20/21+2.5% at age 29/30 and
6.4% at age 40/41; the cumulative incidence rates for
the six interviews are 0.8% at age 20/21, 2.1% at age
22/23, 3.4% at age 27/28, 5.1% at age 29/30, 10.3% at
age 34/35, and 14.0% at age 40/41 (Fig. 1).
The age of onset of anxiety symptoms was
15.6 years. There was no difference between the sub-
groups of the GAD severity spectrum. Over 75% of
GAD cases manifested their first GAD symptoms be-
fore the age of 20/21 years. Women prevailed in all
subgroups of the GAD spectrum (Table 1).
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Fig. 1 Cumulative incidence rates of DSM-III GAD from age 20/21 to 40/
41 years
39
j Course of GAD
Annual presence of symptoms and treatment across
22 years
Subjects with DSM-III GAD suffered from anxiety in
41.4% (median 37.5%) of all 22 years in which symp-
toms were assessed, and were treated for anxiety in
8.9% (median 4.5%) of all years. Comparing the two
decades 1978–1988 and 1989–1999, we found that the
percentage of symptomatic years among DSM-III GAD
subjects increased non-significantly from 38.7%
(±29.5) in the third decade of life to 43.0% (±34.3) in the
fourth decade of life (P < 0.12), and the percentage of
years with treatment increased significantly from 6.1%
(±12.2) to 12.0% (±20.0) (P < 0.02). Table 1 shows the
results for 6-month and DSM-III GAD separately. On
comparing the four GAD groups, there was no clear
difference or systematic trend showing 6-month GAD
to be more symptomatic or more likely to be treated
than 2-week GAD, between the ages of 20 and 40 years.
Follow-up and follow-back of DSM-III GAD
Subjects could receive a GAD diagnosis at any inter-
view during the prospective study. The average
follow-up period of the 105 GAD subjects was 7.6
(SD = 6.45) years, with a median of 6.0 years.
Follow-ups to age 34/35 and 40/41: During the first
five interview waves (up to age 34/35) 83 DSM-III
GAD cases were identified cumulatively, 62 of whom
were followed up until the age of 40/41, when only
18% still met diagnostic criteria, 5% manifested GAD
syndromes shorter than 1 month, 24% had residual
symptoms and 53% were symptom-free.
At the age of 34/35 (1993) 20 cases of DSM-III-R
GAD (6 months’ duration) were diagnosed and 14 of
them were followed-up until the age of 40/41: 57.1%
had become symptom-free, 14.3% manifested symp-
toms, 14.3% were diagnosed as DSM-III GAD and
7.1% as 6-month DSM-III-R GAD; a residual 7.1% had
developed RBA.
Follow-up to the individual last interview: 75 cases
of 1+ month GAD had at least one follow-up inter-
view. At their individual last follow-up, 12 of those 75
cases (16%) still received a 1+ month GAD diagnosis,
22 (29%) were diagnosed with 2-week GAD, RBA or
anxiety symptoms, but the majority of 39 cases (52%)
were symptom-free. The mean duration of follow-up
of the 75 cases was 10.6 years (median = 11 years,
SD = 5.1, range 2–20 years).
Figure 2 indicates all movements between sub-
groups on the GAD spectrum across the six inter-
Table 1 Incidence, age of onset and course of GAD syndromes (1–4) and anxiety symptoms (5)
GAD syndromes Anxiety sympt. Othersa
6 months 1 month 2 weeks RBA P
1 2 3 4 5 6 1–6 1–4
Subjects (N) 31 74 23 91 169 203
Males 11 32 7 35 81 126
Females 20 42 16 56 88 77 0.0002 0.0001
F/M ratio 1.8 1.3 2.3 1.6 1.1 0.6
Cumulative incidence (%) 3.2 10.8 2.5 8.7 27.9 47.0
Males 2.5 9.7 0.6 5.2 24.0 58.1
Females 3.9 11.8 4.3 12.2 31.7 36.3 0.0001 0.0001
F/M ratio 1.6 1.2 7.9 2.3 1.6 0.6
Age of onset of anxiety sx.
Mean (SD) 13.2 (7.3) 16.5 (8.4) 15.5 (6.5) 14.4 (7.0) 17.5 (7.4) 14.7 (8.0) 0.001 0.13
Median 13.5 18 18 15 19 14
Q1–Q3 7–18 8–20 12–20 8–20 12–21 8–20
% years symptomatic (mean, SD)
1978–1999 (22 years) 50.9 (26.2) 36.0 (23.9) 47.2 (25.3) 45.6 (28.2) 25.6 (21.0) 6.4 (13.3) 0.0001 0.06
1978–1988 (11 years) 40.8 (27.9) 35.7 (27.2) 41.8 (28.3) 48.8 (30.5) 29.1 (25.6) 7.1 (14.6) 0.0001 0.84
1989–1999 (11 years) 61.9 (33.8) 33.7 (30.3) 51.1 (35.1) 34.4 (37.4) 16.3 (24.0) 1.9 (8.7) 0.0001 0.003
% years treated (mean, SD)
1978–1999 15.1 (18.3) 6.5 (10.1) 14.1 (25.5) 10.4 (15.8) 3.6 (8.3) 0.1 (1.1) 0.0001 0.14
1978–1988 9.6 (16.7) 3.7 (8.0) 10.1 (23.3) 9.9 (17.8) 2.6 (7.0) 0.0 (0.0) 0.0001 0.65
1989–1999 19.4 (25.3) 9.7 (16.3) 17.4 (29.3) 8.8 (19.0) 3.8 (11.8) 0.3 (2.7) 0.0001 0.25
Lifetime treatment rate for anxiety 71.0 56.8 56.5 53.9 33.7 4.4 0.0001 0.42
Persistent anxiety (weighted prevalence) 2.7 1.4 0 0.9 0.6 0
At individually last interview
Number of days in previous year with
anxiety symptoms (median)
360 50 32.5 35 14 0 0.0001 0.0001
Number of days in previous year with
anxiety or panic symptoms (median)
360 50 32.5 30 14 2 0.0001 0.0001
aOthers include also subjects with anxiety symptoms occurring outside of the interview years (lifetime prevalence was not assessed)
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views (each covering 12 months). Of the 75 cases of
1+ month GAD who were re-interviewed at least
once, 21% again manifested GAD, 19% sub-threshold
syndromes and 44% symptoms, but the majority of
those 75 cases (76%) were also symptom-free at one
or other subsequent interview. These figures illus-
trate the considerable movement between the sub-
groups over time. A similar finding is obtained by
following back subjects’ last episodes of 1+month
GAD.
Transition between subgroups of the GAD spectrum
The temporal pattern of the changes within subgroups
of the GAD spectrum is shown in more detail in
Fig. 3. For this purpose waves1 (age 20/21) and 2 (age
22/23) and waves 3 (age 27/28) and 4 (age 29/30) were
unified. Most changes were from a symptom-free
status to a diagnostic subgroup and vice versa, which
may be interpreted as a recurrent course along the
GAD spectrum with symptom-free intervals.
Across the four age groups (20/23; 27/30; 34/35; 40/
41) the stability of DSM-III-defined GAD increased
from 9 to 21%, interpretable as a growing trend to
recurrence or chronicity in GAD subjects. After the
ages of 30 and 34/35, 7 and 11% respectively of RBA
(brief GA syndromes) had developed into DSM-III
GAD five years later. These findings are compatible
with the increased annual incidence rates described
above.
Improvement and deterioration of anxiety: On our
GAD severity spectrum comprising four categories
(no symptoms, symptoms, subthreshold syndromes
<1 month, 1+ month GAD), subjects were observed
to move up- and downwards over time. This change
in severity was analysed by comparing the individual
first and last completed interviews; longitudinally 138
cases showed an improvement, 110 cases a deterio-
ration and 128 subjects no change at all. The
remaining 215 subjects never manifested anxiety
symptoms and were not included in this calculation.
A histogram showing the distribution of changes is
GAD
Sub-GAD
Anx sx
GAD
Sub-GAD
Anx sx
No sxNo sx
Follow-backof last episodeFollow-up of first episode
20%
16%
19%
21%
86%76%
55%44%
GAD
N=75
GAD
N=97
Fig. 2 Follow-up of individually first and follow-
back of individually last episode of 1+month GAD.
The categories are not mutually exclusive in order
to show all changes
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AgeFig. 3 Temporal shifts within the GAD
spectrum
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given in Fig. 4. Most common were no change or a
switch to the nearest less severe category of the anx-
iety spectrum. Overall, then, the condition in most
subjects either did not deteriorate or even improved.
Persistence of GAD
A key question investigated by this paper is whether
GAD is persistent. Here, ‘persistence’ was defined as
the presence of anxiety symptoms almost every day
during the twelve months prior to an interview. At the
individual last interview 5 of 75 (7%) 1-month DSM-
III GAD cases had become persistent, and 1 of 14
(7%) 6-month DSM-III-R GAD cases diagnosed at age
34/35 years had become persistent at the age of 40/
41 years.
As regards the stability of persistence: 30 subjects
with DSM-III GAD met the persistence criterion at
least once; during the follow-up 27 (90%) of them
showed no further persistence, and in only one of the
remaining three subjects was GAD always persistent,
whereas the other two changed status repeatedly. Of
further interest is the follow-up of 10 cases of per-
sistent 6-month DSM-III-R GAD diagnosed at the age
of 34/35 years: all had ceased to meet the criteria for
persistence at the age of 40/41 years.
Social conditions and treatment at the individual last
follow-up
Subjects with GAD syndromes had a higher income
than those with no GAD diagnosis (including symp-
tom carriers and symptom-free subjects) (Table 2).
They were more often married, separated or divorced
than controls and more often suffering from a chronic
physical disease. In addition, the 6-month GAD group
followed over 5 years did not differ in social outcome
variables from other subgroups of the GAD spectrum
except, again, by a higher income. A similar propor-
tion of subjects with 6-month and 1-month GAD were
being treated at the last follow up: 6-month GAD:
25.8% and DSM-III GAD: 21.6% (Table 2).
j Treated vs. non-treated DSM-III GAD
Treatment was defined as treatment for GAD syn-
dromes by MD’s or psychologists. 67 (58%) of GAD
subjects were professionally treated over their life-
time. There was no gender difference, either in raw
numbers or in weighted prevalence rates between
treated and non-treated groups (Table 3). Persistent
anxiety was twice as frequent among treated subjects
(48%). The latter were also symptomatic over more
years than non-treated subjects (50.5% vs. 26.7% of
the 22 observed years). Treated subjects felt signifi-
cantly more distressed and more impaired at work by
their anxiety.
Among those who had been treated, the condition
of 52% worsened between their first and last indi-
vidual interviews, whereas 22% improved and 27%
did not change. The corresponding figures for sub-
jects who had never been treated for GAD were 49%
(worse), 20% (improved) and 32% (no change).
Table 3 shows the much higher overall comorbid-
ity among treated than among untreated GAD sub-
jects. However, comorbidity with major depressive
disorder did not differ significantly between treated
and untreated individuals and even showed a trend in
the opposite direction.
A multivariable logistic regression including as
predictors sex and the diagnoses unipolar depression,
bipolar II disorder (BP-II), social phobia, obsessive-
compulsive syndrome, binge eating, alcohol abuse or
dependence, cannabis abuse or dependence, and to-
bacco abuse or dependence found significantly higher
odds for BP-II (OR = 2.9, 95% C.I. 1.03–8.32,
P < 0.04) and social phobia (OR = 3.7, 95% C.I. 1.22–
11.07, P < 0.02), and a trend to higher odds for can-
nabis abuse/dependence (OR = 4.0, 95% C.I. 80–
19.96, P < 0.10) in treated compared to non-treated
GAD cases.
Discussion
We used a spectrum approach to describe the course
of GAD, with analysis of the movements between four
subcategories: DSM-III GAD, subthreshold GAD
(<1 month), anxiety symptoms and no symptoms. A
comparable approach was used in long-term studies
0
−3 −2 −1 0 1 2 3
50
100
150
change
N
Fig. 4 Histogram of changes in anxiety subgroup between first and last
completed interview. The first interview for all subjects was the one completed
at age 20; the last completed interview differed for different subjects. The
change was quantified in terms of units corresponding to the change of one
subgroup of anxiety to the next more or less severe subgroup. Subgroups in
order of ascending severity are ‘‘no anxiety’’, ‘‘anxiety symptoms’’, ‘‘<1 month-
GAD’’, and ‘‘1+ month GAD’’. As an example, a subject who changed from ‘‘no
anxiety’’ at his or her first interview to ‘‘1+ month GAD’’ at his or her last
interview would be assigned a change of +3. A subject who changed from
‘‘<1 month-GAD’’ at the first to ‘‘anxiety symptoms’’ at the last interview
would be assigned a change of )1
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of depressive disorders [7, 19]. As a subthreshold
syndrome, the GAD spectrum also includes recurrent
brief anxiety, which was earlier found to form a
bridge to panic attacks [5].
The prevalence data illustrate that GAD syn-
dromes of 1–5 months’ duration and brief manifes-
tations under 2 weeks are much more common than
syndromes lasting 6 months or more. We concen-
trated on DSM-III 1-month GAD syndromes because
this enabled us to analyse the course across 20 years
from 1979 to 1999: in addition, this subgroup has
been shown in clinical terms to be as valid as using
a sub-group with 6-month GAD. In an earlier
analysis [5] we found, in agreement with two other
epidemiological studies, that generalized anxiety
syndromes of varying length (2-weeks, 1 month, 3
and 6 months) were homogeneous and did not dif-
fer significantly in terms of treatment rates,
impairment, distress, family history or comorbidity
with major depressive episodes, bipolar disorder or
suicide attempts [11, 21]. Further research based on
new epidemiological samples is needed to clarify
whether a minimum duration of 2 weeks of anxiety
could be used as a diagnostic cut-off. The treatment
rates and years with treatment found in our study
would be compatible with this shorter temporal
criterion, as originally used in the Research Diag-
nostic Criteria. The minimum duration for GAD was
extended from 1 month (DSM-III) to 6 months
(DSM-III-R, DSM-IV) in order to reduce the asso-
ciation with major depression, however the associ-
ation of GAD with major depressive episodes has
been shown to be independent of the duration of
GAD [5].
On the diagnostic level the cumulative incidence
rate of GAD increased after the age of 30 years, con-
firming the results of larger epidemiological studies
[14, 29] which describe a positive correlation of onset
with age. This is compatible with the findings of
Carter et al. [14], who reported an increase in the
annual prevalence rates up to the age of 55 years. In
our younger age group DSM-III GAD was very com-
mon. By contrast Wittchen [27] found that GAD is
uncommon before 25 years of age which may partially
be a consequence of the 6-month criterion of DSM-
III-R and DSM-IV. We can hypothesise that in
adulthood, age may be associated with an increasing
incidence of GAD. The onset of characteristic anxiety
symptoms (not diagnoses) occurred in 75% of GAD
cases before 21 and tended to be earlier in 6-month
GAD (median 13.5 years) than in 1-month GAD
(18 years, P < 0.13, but note the small numbers).
75 of 105 diagnosed GAD cases had at least one
follow-up. Like major depression the course of GAD
was recurrent in the majority of cases: in at least one
follow-up interview, 21% were diagnosed again as
GAD, 19% manifested sub-diagnostic anxiety syn-
dromes, and 76% were symptom-free (numbers not
mutually exclusive). Across all interviews only one
case of DSM-III GAD and no cases of DSM-IIIR GAD
were always persistent.
The final outcome at the individual last follow-up
was persistent (chronic) in only 7% of DSM-III and
DSM-III-R GAD cases. For a considerable proportion
of them the outcome was favourable: of 75 subjects
previously diagnosed as having DSM-III GAD 58%
had been symptom-free for at least 1 year at the age of
35 years, and 63% at the age of 40 years. For the few
Table 2 Social variables at individually last interview
6-months
GAD
1-month
GAD
<1 month
GAD/RBA
Anx sx No sx P
5 4 3 2 1 1–5
N 31 74 114 169 203
Lives alone 25.8% 21.6% 19.3% 17.8% 16.3% 0.67
Part time employed 48.3 52.4 44.6 38.2 17.3 0.001a
Fully employed 51.7 47.6 55.4 61.8 82.7
Housewife 29.0 32.4 32.5 33.1 16.3 0.001
Receives benefits 15.4 13.8 13.2 14.8 7.6 0.58
Incomeb
<1,500 CHF 6.7 0 0 2.2 1.5 0.14
<2,500 CHF 0 3.3 10.0 9.8 18.9
<4,000 CHF 13.3 10.0 22.0 16.3 16.7
>4,000 CHF 80.0 86.7 68.0 71.7 62.9
Any chronic illness 51.6 40.5 34.7 39.5 22.0 0.002
Never married 29.0 33.8 43.0 33.1 52.7 0.0007
Ever divorced or
separated
35.5 17.6 18.4 13.0 9.4 0.002
Treated 25.8 21.6 13.9 9.2 0 0.0001
aInteraction with sex significant (P = 0.001): less women are fully employed
bOnly for employed subjects (N = 324); an ordered logistic regression model showed significant increases in income in subjects with 1+month GAD (OR=3.2 [1.7–
6.0]) compared to non-symptomatic subjects, adjusted for sex and employment status. Female sex, even when corrected for employment status, was associated with
lower incomes (OR = 0.35 [0.19–0.65])
CHF = SWISS FRANCS
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6-month DSM-III-R cases followed-up from 35 to 41
the findings did not differ: 8 of 14 cases (57%) became
symptom free. The relatively good outcome of GAD in
our epidemiological study is comparable with the 12-
year patient follow-up study of Bruce et al. [13]
mentioned in the introduction. These results are
clearly at odds with the common affirmation that
GAD has a generally chronic course, but are com-
patible with the description of a waxing and waning
course: however our data show that waning is more
common than waxing.
As expected, treated GAD subjects were more se-
verely affected than non-treated subjects in terms of
distress, impairment at work and persistence of the
disorder. Surprisingly, there was no gender difference
in lifetime prevalence rates between treated and non-
treated subjects. The finding that treatment of GAD was
associated with comorbidity was not surprising. Bipo-
lar-II disorder was much more strongly associated than
MDD with treated GAD, a finding compatible with the
close association of BP-II with anxiety disorders [4].
Limitations
The study sample is relatively small and there was an
attrition rate of 38.5% over 20 years of observation.
Our group of DSM-III-R GAD subjects was too small
(N = 16) and their follow-up over only 6 years too
short to allow definitive conclusions, but our pre-
liminary findings suggest their course did not differ
from those for DSM-III GAD. The course of GAD in
subjects older than 40 years may be worse than that in
younger adults.
Conclusions
Our 20-year prospective follow-up data on (1-month)
DSM-III-defined GAD demonstrate a recurrent course
of the disorder with a chronicity rate of under 20%.
These results question the current rather pessimistic
view that the disorder has a generally chronic course,
Table 3 Treated LT (life-time) versus non-treated GAD
DSM-III GAD P
Treated LT Non-treated Othersb (1–3) (1–2)
(1) (2) (3)
N 67 38 486
Males 27 16 249
Females 40 22 137 0.16 0.86
Cumulative incidence 6.1% 7.8% 86.1%
Males 5.3 6.9 87.8
Females 6.9 8.7 84.4 0.05 0.89
Treated 1986–1999 by
Psychiatrist 20.9 – 2.3
G.P. 19.4 – 5.6
Psychologist 11.9 – 3.1
Distress 0–100 (means, s) 86.0 (14.1) 65.6 (21.9) . 0.0000
Impaired at work 0–100 44.4 (32.4) 19.9 (23.7) 0.0003
Medicationa (81–99) 35.8 5.3 6.9 0.0001 0.002
None 64.2 94.7 93.1
Antidepressants (86–99) 23.9 7.9 6.6 0.0001 0.05
Benzodiazepinesa (86–99) 7.5 – 2.0 0.02 0.09
% years w. symptoms 50.5 (24.4) 26.7 (20.6) 22.7 (25.3) 0.0000 0.0000
Median 52.9 20.5 13.6
Q1–Q3 31.8–68.2 12.5–36.4 0.0–33.3
Persistent anxiety 47.8 23.7 0.02
Outcome at individual last interview 0.0001 0.41
GAD 38.8 42.1 0.0
Sub-threshold GAD 9.0 5.3 5.5
Anxiety symptoms 17.9 7.9 15.4
No symptoms 34.3 44.7 79.1
Comorbidity
Major depr. disorder 22.4 31.6 15.2 0.30
Bipolar-II disorder 40.3 15.8 11.5 0.004
Social phobia 34.3 13.2 11.5 0.02
Obs.-compulsive syndrome 38,8 23.7 15.6 0.12
Binge eating 25.4 7.9 11.7 0.03
Alcohol use disorder 35.8 21.2 19.1 0.12
Cannabis weekly 19.4 5.3 26.1 0.05
Any drug abuse 47.8 21.1 10.1 0.007
aSelf-medication
bSubjects without a diagnosis of GAD
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and suggest there may be room for therapeutic opti-
mism as proposed by Helen Lester and Linda Gask
[23]. At the same time, the degree of recurrences
illustrate the need to develop effective long-term
prophylactic strategies.
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